8-K Announcements
6Material company update
May 12, 2026·SEC
Material company update
Mar 2, 2026·SEC
Material company update
Nov 5, 2025·SEC
Sionna Therapeutics, Inc.(SION)Earnings, Financials & Key Ratios
SION•NASDAQ
$42.18
Price updated Jun 27, 2026
AboutSionna Therapeutics, Inc. is a biopharmaceutical company. The Company provides treatment paradigm for cystic fibrosis patients by developing medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator.Show more
- Revenue$0
- EBITDA-$88M-26.4%
- Net Income-$75M-22.0%
- EPS (Diluted)-1.88-34.3%
- ROE-105.18%
SION Price & Volume
Sionna Therapeutics, Inc. (SION) stock price & volume — 10-year historical chart
Loading chart...
Persistent Clinical Burn Challenges Capital Market Dependency
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial Position:Vulnerable
Cash Flow:Burning
Primary Risk:Clinical trial execution failure
"Sionna Therapeutics faces a precarious financial outlook as its pre-revenue clinical development model continues to drive significant quarterly operating losses, reaching $29.6 million in 2026Q1. The company's reliance on equity-based financing to sustain its $19.0 million quarterly R&D expenditure creates substantial dilution risk for shareholders. Investors should monitor the firm's ability to extend its $63.3 million cash runway, as the current trajectory of asset depletion and accumulated deficits of $283.1 million suggests limited strategic flexibility without further capital raises."
Verdict Logic
the company's reliance on equity-based funding to cover a $29.6 million quarterly operating loss, combined with an accumulated deficit of $283.1 million, presents significant long-term dilution risks for investors.
SION Growth Metrics
Sionna Therapeutics, Inc. (SION) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-22.86%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-21.98%
Return on Capital
10 Years-58.71%
5 Years-58.71%
3 Years-60.85%
Last Year-36.35%
SION Recent Earnings
Sionna Therapeutics, Inc. (SION) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 3/7 qtrs (50%)
Q2 2026Latest
May 12, 2026Metric
Actual
Est
EPS
$0.60-15.4%
$0.52
Rev
—
—
Q2 2026
Mar 2, 2026Metric
Actual
Est
EPS
$0.46+14.7%
$0.54
Rev
—
—
Q4 2025
Nov 5, 2025Metric
Actual
Est
EPS
$0.46+11.5%
$0.52
Rev
—
—
Q3 2025
Aug 11, 2025Metric
Actual
Est
EPS
$0.41+39.7%
$0.68
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 12, 2026 | $0.60vs $0.52-15.4% | — |
| Q2 2026 | Mar 2, 2026 | $0.46vs $0.54+14.7% | — |
| Q4 2025 | Nov 5, 2025 | $0.46vs $0.52+11.5% | — |
| Q3 2025 | Aug 11, 2025 | $0.41vs $0.68+39.7% | — |
Based on last 7 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Sionna Therapeutics, Inc. (SION)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $42.18 | $1.9B | -22.44 | — | — | -105.18% | — | |
| $491.34 | $124.98B | 32.07 | 9.57% | 35.4% | 23.93% | — | |
| $251.52 | $444.38B | 106.13 | 8.57% | 5.79% | 67.46% | — | |
| $84.43 | $7B | 10.85 | 114.51% | -22.58% | — | — | |
| $30.77 | $3.03B | -5.28 | 20.13% | -91.03% | — | — | |
| $372.25 | $10.97B | 54.42 | 33.94% | 53.92% | 19.25% | — |
Compare SION vs Peers
Sionna Therapeutics, Inc. (SION) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
SION SEC Filings & Documents
Sionna Therapeutics, Inc. (SION) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when SION posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
SION Frequently Asked Questions
Sionna Therapeutics, Inc. (SION) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is SION profitable?
Sionna Therapeutics, Inc. (SION) reported a net loss of $85.6M for fiscal year 2025.
Dividend & Returns
What is SION's return on equity?
Sionna Therapeutics, Inc. (SION) has a return on equity (ROE) of -105.2%. Negative ROE indicates the company is unprofitable.
What is Sionna Therapeutics, Inc.'s free cash flow?
Sionna Therapeutics, Inc. (SION) had negative free cash flow of $72.1M in fiscal year 2025, likely due to heavy capital investments.